Article info
PDFPostScript
Letter
Immunogenicity and safety profile of the monovalent A/H1N1 MF59-adjuvanted vaccine in patients affected by cystic fibrosis
- Correspondence to Vincenzina Lucidi, Department of Pediatric Medicine, Unit of Cystic Fibrosis, Bambino Gesù Children's Hospital, P.zza S. Onofrio n. 4, 00165 Rome, Italy; vincenzina.lucidi{at}opbg.net
Citation
Immunogenicity and safety profile of the monovalent A/H1N1 MF59-adjuvanted vaccine in patients affected by cystic fibrosis
Publication history
- Accepted November 25, 2010
- First published January 12, 2011.
Online issue publication
February 18, 2011
Article Versions
- Previous version (12 January 2011).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.